Illumina (ILMN) Resumen de Acciones
Illumina, Inc. ofrece soluciones basadas en secuenciación y arrays para análisis genéticos y genómicos en América, Europa, China, Asia-Pacífico, Oriente Medio y África. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 3/6 |
| Crecimiento futuro | 2/6 |
| Rendimiento pasado | 3/6 |
| Salud financiera | 5/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
ILMN Community Fair Values
Create NarrativeSee what 88 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Illumina, Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$188.68 |
| Máximo en las últimas 52 semanas | US$189.46 |
| Mínimo de 52 semanas | US$88.00 |
| Beta | 1.47 |
| Cambio en 1 mes | 16.24% |
| Variación en 3 meses | 47.71% |
| Cambio de 1 año | 87.18% |
| Variación en 3 años | 2.92% |
| Variación en 5 años | -60.43% |
| Variación desde la OPV | 863.34% |
Noticias y actualizaciones recientes
Actualización de narrativa • Jun 29
ILMN: Clinical Execution And Sector Funding Support A Cautiously Balanced Outlook
The analyst fair value estimate for Illumina has been lifted by $10 to $185, reflecting higher Street price targets and analyst expectations for stronger customer spending and margins, supported by recent research, survey feedback, and sector funding trends. Analyst Commentary Recent Street research around Illumina points to a more constructive tone, with several bullish analysts highlighting improving customer sentiment, sector funding trends, and clearer execution on the clinical side.
Actualización de narrativa • Jun 15
ILMN: Future Returns Will Hinge On Clinical Sequencing Momentum And Customer Stickiness
Narrative Update: Illumina The analyst price target underpinning this Illumina narrative has been raised from about $136 to $147, reflecting updated assumptions around customer stickiness, clinical sequencing momentum, and expectations for higher instrument and consumables spending highlighted in recent research. Analyst Commentary Recent research on Illumina reflects a mix of enthusiasm about the company’s position in sequencing markets and some ongoing caution around execution and valuation, with several major firms updating ratings and price targets.Recent updates
Actualización de narrativa • Jun 29
ILMN: Clinical Execution And Sector Funding Support A Cautiously Balanced Outlook
The analyst fair value estimate for Illumina has been lifted by $10 to $185, reflecting higher Street price targets and analyst expectations for stronger customer spending and margins, supported by recent research, survey feedback, and sector funding trends. Analyst Commentary Recent Street research around Illumina points to a more constructive tone, with several bullish analysts highlighting improving customer sentiment, sector funding trends, and clearer execution on the clinical side.Actualización de narrativa • Jun 15
ILMN: Future Returns Will Hinge On Clinical Sequencing Momentum And Customer Stickiness
Narrative Update: Illumina The analyst price target underpinning this Illumina narrative has been raised from about $136 to $147, reflecting updated assumptions around customer stickiness, clinical sequencing momentum, and expectations for higher instrument and consumables spending highlighted in recent research. Analyst Commentary Recent research on Illumina reflects a mix of enthusiasm about the company’s position in sequencing markets and some ongoing caution around execution and valuation, with several major firms updating ratings and price targets.Actualización de narrativa • Jun 01
ILMN: Clinical Momentum And Softer Competition Will Shape A Balanced Outlook
Analysts have lifted the fair value estimate for Illumina from $156.51 to $175.00, citing Street research that points to building clinical momentum, easing competitive concerns, and a series of higher price targets from several firms. Analyst Commentary Recent Street research on Illumina has tilted more constructive, with several bullish analysts pointing to improving clinical traction and a less intense competitive backdrop as key supports for the stock.Artículo de análisis • May 11
We Think That There Are Issues Underlying Illumina's (NASDAQ:ILMN) Earnings
Unsurprisingly, Illumina, Inc.'s ( NASDAQ:ILMN ) stock price was strong on the back of its healthy earnings report. We...
Actualización de narrativa • Apr 30
ILMN: Policy And Execution Risks Will Likely Outweigh Supportive Genome Consumable Pricing
Illumina's analyst-derived fair value has shifted modestly lower from $88.35 to $87.05 as analysts balance mixed target changes and view Roche's less aggressive genome pricing as a near term positive that supports assumptions for slightly stronger revenue growth and profit margins, along with a marginally lower future P/E. Analyst Commentary Street research around Illumina reflects a mix of views, with some analysts highlighting potential upside from competitive pricing developments and others trimming price targets in response to ongoing execution and valuation questions.Actualización de narrativa • Apr 15
ILMN: Future Returns Will Depend On Pricing Power And 2026 Tools Demand
Analysts have kept the fair value estimate for Illumina steady at $136.11 per share, with a mix of recent price target increases and trims reflecting updated views on growth, profitability, and competitive pricing after Roche's latest genome sequencing announcement. Analyst Commentary Recent research suggests that views on Illumina are mixed, with the Roche Axelios pricing helping sentiment while target changes reflect different views on execution risk and growth visibility.Seeking Alpha • Apr 10
Illumina: Competitive Threats Priced In
Summary Illumina fundamentals are improving, with FY26 expected to return to positive growth and enable operating leverage. Competition from Roche and others is a risk, but recent news appears priced in; shares have stabilized since the Roche Axelios reveal. FY26 guidance calls for 2% organic growth, EBIT margin expansion of 3% YoY, and further upside from the Somalogic acquisition. My DCF model supports a BUY rating with a $156 target price, implying 22% upside as margin expansion and NovaSeq X mix drive value. Read the full article on Seeking AlphaActualización de narrativa • Apr 01
ILMN: Future Returns Will Depend On 2026 Tools Demand And Competitive Pricing
Illumina's analyst price target nudged up to about $136, as analysts point to slightly firmer revenue growth assumptions, a steady profit margin outlook, and supportive read-through from recent Street research, including Roche's less aggressive genome pricing. Analyst Commentary Street research around Illumina has turned more active, with several firms adjusting price targets and updating views on genomics demand and competitive risks.Actualización de narrativa • Mar 18
ILMN: Future Returns Will Hinge On China Recovery And 2026 Tools Demand
Illumina's updated analyst price target sits slightly higher at about $136, with analysts citing firmer revenue and margin assumptions, a modestly higher discount rate, and supportive recent commentary on competitive pricing for whole genome sequencing consumables. Analyst Commentary Recent Street research on Illumina reflects a mix of optimism and caution, with several firms adjusting price targets and reassessing the setup for the next couple of years.Actualización de narrativa • Mar 04
ILMN: Policy And Execution Risks Will Likely Limit Benefits From Supportive Consumables Pricing
Illumina's analyst price targets have seen a modest upward reset, with a slightly higher fair value estimate of $88.35. This is supported by Street research that highlights firmer competitive pricing in sequencing consumables and a range of recent target revisions tied to updated views on growth, margins, discount rates, and future P/E assumptions.Actualización de narrativa • Feb 18
ILMN: Policy And Execution Risks Will Likely Restrain Tools Thesis Upside
Illumina's updated analyst price target has increased to $87.97 from $80.00. This reflects analysts' mixed but generally more constructive views as they adjust for revised revenue growth, profit margin and future P/E assumptions following a series of recent target changes across the Street.Actualización de narrativa • Feb 03
ILMN: Future Returns Will Depend On China Access And 2026 Execution
Narrative Update: Illumina Analyst Target Shift Our Analyst Price Target for Illumina moves modestly higher by about $4 per share as analysts cite updated views on revenue growth, profit margins, and future P/E multiples following a series of recent price target increases across the Street. Analyst Commentary Bullish and cautious voices are both weighing in on Illumina, and most of the recent activity centers on refreshed views for 2026, broader life science tools demand, and where valuation might settle after recent share moves.Actualización de narrativa • Jan 20
ILMN: Future Returns Will Depend On China Recovery And Execution Through 2026
Analysts have raised their implied fair value for Illumina by about $12 to approximately $132 per share, reflecting updated views on revenue growth, profit margins and future P/E multiples, supported by a series of recent price target increases across the Street. Analyst Commentary Recent research updates cluster around higher price targets and mixed views on how reliably Illumina can deliver against those expectations.Actualización de narrativa • Jan 06
ILMN: China Export Restrictions Will Likely Cap Upside Despite Cost Efficiencies
Analysts have raised their price targets on Illumina to a range of roughly $100 to $195, citing recovering end markets, healthier procedure and CapEx trends into 2026, and cost efficiencies highlighted in recent quarterly results, even as they continue to flag limited visibility and ongoing challenges in China. Analyst Commentary Recent research updates present a mixed picture for Illumina, with higher price targets sitting alongside ongoing questions around visibility, execution, and regional headwinds.Actualización de narrativa • Dec 14
ILMN: China Export Risks Will Likely Limit Upside Despite Recent Optimism
Analysts raised our implied fair value estimate for Illumina by 7 dollars to 80 dollars per share. This reflects higher revenue growth and profit margin expectations following better than anticipated quarterly results and a series of upward price target revisions across the Street, despite lingering visibility concerns.Actualización de narrativa • Nov 30
ILMN: Future Performance Will Rely On China Market and Operational Execution
Analysts have modestly increased their price targets for Illumina, with the fair value estimate rising by $2.11 per share to $119.84. This reflects confidence in the company’s recent quarterly performance and operational improvements despite ongoing sector headwinds.Actualización de narrativa • Nov 16
ILMN: Future Momentum Will Depend On China Recovery And Efficiency Gains
Analysts have modestly raised their price target on Illumina, increasing fair value estimates from approximately $113.58 to $117.74. This reflects improved revenue growth and operational efficiency, despite mixed business visibility and regional challenges.Artículo de análisis • Nov 09
Illumina, Inc. (NASDAQ:ILMN) Stock Rockets 30% As Investors Are Less Pessimistic Than Expected
The Illumina, Inc. ( NASDAQ:ILMN ) share price has done very well over the last month, posting an excellent gain of...Actualización de narrativa • Nov 01
ILMN: Operational Progress Will Offset Ongoing China Exposure And Sector Uncertainties
Illumina's analyst price target has increased modestly, with the average rising from $111.95 to $113.58. Analysts cite stronger operational performance and revenue growth, even as the company faces ongoing sector and regional challenges.Actualización de narrativa • Sep 04
Next-generation Sequencing Will Expand Clinical Capabilities Despite Risks
Illumina’s unchanged analyst price target reflects a balance between optimism for sector-leading EPS growth and resilience in consumables, and caution around persistent funding pressures, regulatory risks, and macroeconomic uncertainties, resulting in a maintained fair value of $111.95. Analyst Commentary Mixed quarterly performance prompted both positive and conservative price target adjustments, with solid earnings and guidance raises offset by ongoing academic funding pressures.Artículo de análisis • Aug 31
Estimating The Intrinsic Value Of Illumina, Inc. (NASDAQ:ILMN)
Key Insights Illumina's estimated fair value is US$107 based on 2 Stage Free Cash Flow to Equity Current share price of...Artículo de análisis • Aug 08
Illumina (NASDAQ:ILMN) Strong Profits May Be Masking Some Underlying Issues
NasdaqGS:ILMN 1 Year Share Price vs Fair Value Explore Illumina's Fair Values from the Community and select yours...Artículo de análisis • Aug 05
Illumina, Inc. Just Recorded A 76% EPS Beat: Here's What Analysts Are Forecasting Next
NasdaqGS:ILMN 1 Year Share Price vs Fair Value Explore Illumina's Fair Values from the Community and select yours...Artículo de análisis • Jul 09
Illumina, Inc.'s (NASDAQ:ILMN) Shareholders Might Be Looking For Exit
When close to half the companies in the Life Sciences industry in the United States have price-to-sales ratios (or...Seeking Alpha • Mar 27
Is Illumina Undervalued After An 83% Drop In Its Stock Price?
Summary The base and pessimistic DCF models implemented in this article suggest that Illumina is undervalued. Illumina expects to reach a growth rate in its revenues of 6%-9% CAGR by 2027. The DNA sequencing market is expected to grow by 14.90%-21.65% CAGR in the following ten years. Despite the losses that Illumina has incurred due to its GRAIL divestiture, the company will not continue to finance GRAIL in the upcoming years. Read the full article on Seeking AlphaSeeking Alpha • Mar 05
Illumina: Navigating Headwinds As China Bans Instruments And Roche Enters The NGS Race
Summary Illumina faces significant challenges from China's "unreliable entity list" and competition from Roche's new SBX technology, impacting its growth prospects. Despite a 37% stock decline since August, Illumina remains a leader in NGS with promising long-term growth, though the short-term outlook is cautious. Illumina's Q4 financials show improved gross margins and strong free cash flow, but geopolitical risks and modest growth temper optimism. Downgrade to "hold" as competitive and geopolitical risks are priced in, but Illumina's leadership and operational improvements warrant a balanced perspective. Read the full article on Seeking AlphaRentabilidad de los accionistas
| ILMN | US Life Sciences | Mercado US | |
|---|---|---|---|
| 7D | 6.9% | 2.1% | 1.6% |
| 1Y | 87.2% | 16.5% | 18.6% |
Rentabilidad vs. Industria: ILMN superó a la industria US Life Sciences, que obtuvo un rendimiento del 16.5% el año pasado.
Rentabilidad vs. Mercado: ILMN superó al mercado US, que obtuvo un rendimiento del 18.6% el año pasado.
Volatilidad de los precios
| ILMN volatility | |
|---|---|
| ILMN Average Weekly Movement | 6.0% |
| Life Sciences Industry Average Movement | 8.6% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Precio estable de las acciones: ILMN no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de ILMN (6%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1998 | 8,625 | Jacob Thaysen | www.illumina.com |
Illumina, Inc. ofrece soluciones basadas en secuenciación y arrays para análisis genéticos y genómicos en América, Europa, China, Asia-Pacífico, Oriente Medio y África. La empresa ofrece instrumentos y consumibles basados en secuenciación y arrays, que incluyen reactivos, celdas de flujo y preparación de bibliotecas; kits de secuenciación del genoma completo, que secuencian genomas completos de diverso tamaño y complejidad; y kits de resecuenciación dirigida, que secuencian exomas, genes específicos y ARN u otras regiones genómicas de interés. También ofrece secuenciación del genoma completo, genotipado, pruebas prenatales no invasivas y servicios de asistencia de productos.
Resumen de fundamentos de Illumina, Inc.
| Estadísticas fundamentales de ILMN | |
|---|---|
| Capitalización bursátil | US$28.55b |
| Beneficios(TTM) | US$853.00m |
| Ingresos (TTM) | US$4.39b |
33.5x
Ratio precio-beneficio (PE)6.5x
Ratio precio-ventas (PS)¿Está ILMN sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de ILMN | |
|---|---|
| Ingresos | US$4.39b |
| Coste de los ingresos | US$1.39b |
| Beneficio bruto | US$3.00b |
| Otros gastos | US$2.15b |
| Beneficios | US$853.00m |
Últimos beneficios comunicados
Mar 29, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | 5.64 |
| Margen bruto | 68.29% |
| Margen de beneficio neto | 19.42% |
| Ratio deuda/patrimonio | 74.3% |
¿Cómo se ha desempeñado ILMN a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/07/05 18:35 |
| Precio de las acciones al final del día | 2026/07/02 00:00 |
| Beneficios | 2026/03/29 |
| Ingresos anuales | 2025/12/28 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también contamos con guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Illumina, Inc. está cubierta por 45 analistas. 18 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Catherine Ramsey Schulte | Baird |
| Luke Sergott | Barclays |